Taysha Gene Therapies (TSHA) Long-Term Debt Issuances (2020 - 2021)
Taysha Gene Therapies (TSHA) posted Long-Term Debt Issuances of $10.0 million for Q4 2021, up 36937.04% sequentially from $27000.0 in Q2 2020.
Powered by 
Analysis
Taysha Gene Therapies (TSHA) Long-Term Debt Issuances (2020 - 2021) Analysis & Trends
Taysha Gene Therapies has reported Long-Term Debt Issuances for 2 years, with the latest figure at $10.0 million in Q4 2021.
- Quarterly Long-Term Debt Issuances changed N/A year-over-year to $10.0 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $10.0 million (up 499.34% YoY) and the FY2021 annual result came in at $10.0 million, up 497.73% from the prior year.
- Long-Term Debt Issuances advanced to $10.0 million in Q4 2021 per TSHA's latest filing, from $27000.0 in the prior quarter.
- Over five years, Long-Term Debt Issuances peaked at $10.0 million in Q4 2021 and troughed at $27000.0 in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Taysha Gene Therapies | 2.06 Bn | 2.06 Bn | - | - |